Introduction {#Sec1}
============

Acute bacterial skin and skin structure infections (ABSSSI) are among the most common reasons for visits to the emergency department \[[@CR1]\]. One group at particularly high risk for ABSSSI is injection drug users (IDUs) \[[@CR2]--[@CR5]\]. The high incidence and the high rate of recurrence of ABSSSI in this population are likely due to frequent, repeated injections, injection method (subcutaneous injection), and/or drug mixture (cocaine and heroin, often with contaminants). The lack of aseptic injection methods, including the practice of needle licking, contaminates the injection site and increases the risk for skin infections \[[@CR2], [@CR3], [@CR5], [@CR6]\]. Subcutaneous injection has been strongly associated with the development of purulent infections and cellulitis due to the localized introduction of contaminants, irritants, and bacteria directly into the tissue \[[@CR7], [@CR8]\]. Injection of cocaine and heroin may also increase the risk for ABSSSI because it induces localized irritation and tissue reaction that promote the development of infections \[[@CR8]\].

Among IDUs, the most commonly identified causative pathogens for ABSSSI are *Staphylococcus aureus*---including methicillin-resistant *S. aureus* (MRSA) \[[@CR3], [@CR4], [@CR9], [@CR10]\]---and streptococcal species \[[@CR3]\]. However, the bacteriology of ABSSSI in IDUs can be diverse and polymicrobic with infections from nontraditional pathogens---such as those present in the oral flora---commonly seen \[[@CR4], [@CR10]\].

Injection drug users often use emergency departments as their primary source for medical care, with ABSSSI a leading reason for presentation \[[@CR2], [@CR4]\]. Physicians may be faced with many challenges when treating IDUs including poor compliance, delays in seeking medical care, and recurring infections \[[@CR2], [@CR3], [@CR7]\]. Additionally, many IDUs have comorbid mental health illnesses and hepatitis C or HIV coinfection, which may complicate treatment options (e.g., limited mental capacity, immunosuppression, adherence to therapy) \[[@CR2], [@CR11]--[@CR13]\]. Given the numerous challenges associated with treating ABSSSI in IDUs, better understanding of patient and disease characteristics and clinical outcomes in IDUs compared with non-IDUs may help guide the best treatment option for this patient population.

Tedizolid, the active moiety of tedizolid phosphate, is a novel oxazolidinone antibacterial with potent activity against a wide range of Gram-positive pathogens, including MRSA and vancomycin-resistant enterococci \[[@CR14]--[@CR16]\]. Two phase 3 trials, ESTABLISH-1 and ESTABLISH-2, demonstrated the noninferior efficacy of tedizolid (200 mg daily for 6 days) compared with linezolid (600 mg twice daily for 10 days) in patients with ABSSSI \[[@CR17], [@CR18]\]. This post hoc subgroup analysis, using pooled data from the two phase 3 ABSSSI clinical trials, aims to assess the safety and efficacy of tedizolid and linezolid in IDUs and non-IDUs.

Methods {#Sec2}
=======

Study Design and Setting {#Sec3}
------------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study. The study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. ESTABLISH-1 and ESTABLISH-2 were randomized, double-blind, double-dummy, multicenter, multinational, noninferiority, phase 3 clinical trials in patients with ABSSSI. Patients had to have suspected or documented Gram-positive infection from baseline Gram stain or culture to be included in the study. Patients with cellulitis/erysipelas or abscess were not enrolled if there was suspected Gram-negative involvement. Concomitant Gram-negative coverage was only allowed with infected wounds. Methods and results of the individual studies and pooled analysis have been previously published \[[@CR17]--[@CR19]\]. These trials are registered at ClinicalTrials.gov (NCT01170221 and NCT01421511).

Selection of Participants {#Sec4}
-------------------------

The trials enrolled patients older than 18 years (ESTABLISH-1) or older than 12 years (ESTABLISH-2) with ABSSSI (cellulitis/erysipelas, wound infection or major cutaneous abscess). Full details of patient eligibility criteria have been published \[[@CR17], [@CR18]\]. The pooled intent-to-treat (ITT) population from both clinical trials was classified into IDU and non-IDU subgroups based on injection drug use, and all endpoints were evaluated between these groups. Patients who disclosed that they were current or recent users of injection drugs at screening were included in the IDU subpopulation.

Interventions {#Sec5}
-------------

Patients received 200 mg tedizolid phosphate once daily for 6 days or 600 mg linezolid twice daily for 10 days. Patients in ESTABLISH-1 received oral drug. Patients in ESTABLISH-2 received intravenous treatment for 1 day and could subsequently be switched to oral drug at the investigator's discretion if they met two or more of the following criteria: no increase from baseline in primary lesion area, temperature lower than 37.7 °C, no worsening of local signs and symptoms, or improvement of local signs and symptoms at the primary infection site.

Methods and Measurements {#Sec6}
------------------------

Baseline assessments were performed within 24 h before the first dose of study drug (day 1). Patients were evaluated on day 1, day 2, 48--72 h after the first dose, day 7, and day 11 \[end-of-treatment (EOT) visit\]; at the post-therapy evaluation (PTE) visit (7--14 days after the EOT visit); and at the late follow-up (LFU) visit (18--25 days after the EOT visit). Intravenous treatment was delivered in a health care setting, but patients were permitted to take oral study drug at home.

Bacterial pathogens were identified from a blood culture or from culture of a microbiological sample obtained from the primary lesion site by needle aspiration, biopsy, deep swab, incision or other surgical techniques. Pathogens (genus and species) were identified by the central laboratory; local laboratory data were used if central laboratory data were not available.

Outcome Measures {#Sec7}
----------------

The primary endpoint was a ≥ 20% reduction in lesion area \[length × width of erythema, edema or induration (in ESTABLISH-1; only erythema was used to determine lesion size)\] without receipt of rescue antibiotics. Early clinical response was assessed 48--72 h after the first dose of study drug; patients who had received nonstudy systemic antibacterial agents for any reason within 72 h of the first dose were considered nonresponders, per US Food and Drug Administration guidelines \[[@CR20]\]. A key secondary endpoint was late response, which involved investigator-assessed clinical response at the PTE \[7--14 days after the end of therapy (EOT; 11 days after the start of study drug)\], per European Medicines Agency guidelines \[[@CR21]\].

Microbiological response per pathogen at EOT and PTE was also analyzed. A favorable microbiological response was defined as eradication (absence of original baseline pathogens) and presumed eradication (no source specimen to culture in a patient assessed by the investigator as a clinical success).

Safety evaluations included adverse events (AEs), clinical laboratory assessments, vital signs, electrocardiograms, and physical examination.

Analyses {#Sec8}
--------

The ITT population included all randomly assigned patients. Patients with missing data and patients who did not receive study drug were defined as having an indeterminate response and were considered nonresponders for the primary efficacy endpoint. The microbiological ITT (MITT) population included patients with ≥ 1 Gram-positive ABSSSI pathogen isolated at baseline. The clinically evaluable (CE) population included all patients in the ITT analysis set who complied with the protocol and had no major violations. The CE population at PTE (CE-PTE) included patients who completed the study through the PTE assessment without any concomitant systemic antibiotic therapy or other confounding events or factors. The microbiologically evaluable at PTE (ME-PTE) population included all patients in the MITT analysis set who were also in the CE-PTE analysis set. The microbiologically evaluable at end-of-therapy (ME-EOT) population included all patients in the MITT and clinically evaluable at end of therapy (CE-EOT) populations. The safety population included all patients from the MITT population who received ≥ 1 dose of the study drug.

Summaries included frequency and percentages for categorical data, frequency and median for ordinal data, and frequency, mean, standard deviation, and median, minimum and maximum, for quantitative data. Version 9.2 (or higher) of SAS statistical software package was used to provide all summaries and statistical analyses. For both primary and secondary outcomes, 95% confidence intervals (CIs) were adjusted for the study and were calculated using the methodology of Miettinen and Nurminen \[[@CR22]\] to determine the differences in response rates between tedizolid and linezolid treatment arms.

Results {#Sec9}
=======

Characteristics of Study Subjects {#Sec10}
---------------------------------

A total of 1333 patients (664 treated with tedizolid and 669 treated with linezolid) made up the ITT population. Approximately 30% of the pooled ITT population were IDUs: 27.6% (183/664) were in the tedizolid group and 30.8% (206/669) were in the linezolid group. Fewer IDUs were elderly (aged ≥ 65 years) (Table [1](#Tab1){ref-type="table"}). Overall, IDUs had a lower incidence of traditional systemic signs and symptoms of infection than non-IDUs, including fever \[4.9% (19/389) vs. 31.8% (300/944)\], abnormal white blood cell count \[36.8% (143/389) vs. 48.4% (457/944)\], systemic inflammatory response syndrome \[SIRS; 8.2% (32/389) vs. 27.4% (259/944)\], and immature neutrophils \[1.3% (5/389) vs. 11.4% (108/944)\], respectively. Lymphadenopathy, however, was more prevalent in IDUs \[94.3% (367/389)\] than in non-IDUs \[72.1% (681/944)\]. Risk factors, including poor living conditions \[11.3% (44/389) vs. 3.2% (30/944)\] and previous ABSSSI lesion \[33.4% (130/389) vs. 16.9% (160/944); Table [1](#Tab1){ref-type="table"}\], respectively, were more common in IDUs than in non-IDUs. Hepatitis C and concurrent secondary skin infection were approximately nine times \[73.8% (287/389) vs. 7.9% (75/944)\] and three times \[27.0% (105/389) vs. 8.6% (81/944)\] more prevalent in IDUs than in non-IDUs, respectively (Table [1](#Tab1){ref-type="table"}). However, the incidence of each of these comorbidities was similar between the tedizolid and linezolid treatment groups for both IDUs and non-IDUs (Table [1](#Tab1){ref-type="table"}).Table 1Baseline patient characteristics (ITT population)Characteristic, *n* (%)IDUNon-IDUTedizolid (*n* = 183)Linezolid (*n* = 206)All (*n* = 389)Tedizolid (*n* = 481)Linezolid (*n* = 463)All (*N* = 944)Age, mean, years (range)42.3 (19.0--86.0)43.3 (20.0--80.0)42.8 (19.0--86.0)45.4 (17.0--86.0)44.8 (15.0--100.0)45.1 (15.0--100.0) ≥ 65 years5 (2.7)4 (1.9)9 (2.3)67 (13.9)55 (11.9)122 (12.9)Males114 (62.3)143 (69.4)257 (66.1)315 (65.5)269 (58.1)584 (61.9)Fever, ≥ 38 °C9 (4.9)10 (4.9)19 (4.9)150 (31.2)150 (32.4)300 (31.8)WBC, ≥ 10,000 or \< 4000 cells/mm^3^71 (38.8)72 (35.0)143 (36.8)245 (50.9)212 (45.8)457 (48.4)SIRS17 (9.3)15 (7.3)32 (8.2)146 (30.4)113 (24.4)259 (27.4)Lymphadenopathy175 (95.6)192 (93.2)367 (94.3)349 (72.6)332 (71.7)681 (72.1)Immature neutrophils \> 10%1 (0.5)4 (1.9)5 (1.3)64 (13.3)44 (9.5)108 (11.4)Bacteraemia2 (1.1)6 (2.9)8 (2.1)9 (1.9)10 (2.2)19 (2.0)Comorbidities Obesity40 (21.9)60 (29.1)100 (25.7)160 (33.3)172 (37.1)332 (35.2) History of diabetes mellitus9 (4.9)6 (2.9)15 (3.9)49 (10.2)61 (13.2)110 (11.7) HIV positive3 (1.6)3 (1.5)6 (1.5)10 (2.1)5 (1.1)15 (1.6) Hepatitis C positive132 (72.1)155 (75.2)287 (73.8)34 (7.1)41 (8.9)75 (7.9) Concurrent secondary skin infection53 (29.0)52 (25.2)105 (27.0)43 (8.9)38 (8.2)81 (8.6)Risk factors Poor living conditions21 (11.5)23 (11.2)44 (11.3)19 (4.0)11 (2.4)30 (3.2) Prior ABSSSI lesion65 (35.5)65 (31.6)130 (33.4)81 (16.8)79 (17.1)160 (16.9)Type of infection Cellulitis/erysipelas39 (21.3)41 (19.9)80 (20.6)262 (54.5)266 (57.5)528 (55.9) Infected wound93 (50.8)110 (53.4)203 (52.2)102 (21.2)86 (18.6)188 (19.9) Major cutaneous abscess51 (27.9)55 (26.7)106 (27.2)117 (24.4)111 (24.0)228 (24.2)Lesion surface area, mean, cm^3^ (range)244.6 (22.5--1332.0)267.5 (53.3--2397.0)256.8 (22.5--2397.0)376 (28.5--2711.2)383.6 (27.0--5220.0)379.7 (27.0--5220.0) \> 300 cm^3^38 (20.8)43 (20.9)81 (20.8)190 (39.5)177 (38.2)367 (38.9)*ABSSSI* acute bacterial skin and skin structure infections, *IDU* injection drug user, *ITT* intent-to-treat, *SIRS* systemic inflammatory response syndrome, *WBC* white blood cell

The distribution of ABSSSI types differed between IDUs and non-IDUs in both treatment groups. Wound infections, often injection-site infections, were the most common ABSSSI in IDUs \[tedizolid, 50.8% (93/183); linezolid, 53.4% (110/206)\], whereas, in non-IDUs, cellulitis/erysipelas was more prevalent \[tedizolid, 54.5% (262/481); linezolid, 57.5% (266/463); Table [1](#Tab1){ref-type="table"}\].

Patients who used injection drugs presented with a more diverse spectrum of baseline pathogens, including organisms not traditionally associated with ABSSSI, and more frequently had polymicrobial Gram-positive infections (Table [2](#Tab2){ref-type="table"}). Among IDUs and non-IDUs, the most common baseline pathogen was *S. aureus* \[75.2% (212/282) and 85.6% (459/536), respectively\]; the prevalence of methicillin-resistant and methicillin-susceptible *S. aureus* was similar between IDUs \[39.6% (84/212) and 60.8% (129/212), respectively\] and non-IDUs \[44.2% (203/459) and 56.0% (257/459), respectively\]. However, *Streptococcus anginosus* Group \[17% (48/282) in IDUs and 1.9% (10/536) in non-IDUs\] and streptococcal species that generally form part of the oral flora \[including *S. mitis*, *S. salivarius*, *S. sanguinis*, and *S. viridans* Group; 10.3% (29/282) vs. 0.0% in non-IDUs\] were more frequently observed in patients who used injection drugs (Table [2](#Tab2){ref-type="table"}). Infections due to *S. pyogenes* were more frequent in non-IDUs \[9.7% (52/536)\] than IDUs \[0.4% (1/282)\].Table 2Baseline pathogens by injection drug use (MITT population)Pathogens, *n* (%)IDU (*N*= 282)Non-IDU (*N* = 536)Tedizolid (*n* = 129)Linezolid (*n* = 153)Tedizolid (*n* = 277)Linezolid (*n* = 259)Gram-positive aerobes125 (96.9)150 (98.0)274 (98.9)255 (98.5) *Staphylococcus aureus*95 (73.6)117 (76.5)234 (84.5)225 (86.9)  MRSA^a^38 (40.0)46 (39.3)103 (44.0)100 (44.4)  MSSA^a^57 (60.0)72 (61.5)131 (56.0)126 (56.0) *Streptococcus pyogenes*0 (0.0)1 (0.7)33 (11.9)19 (7.3) *Streptococcus anginosus* group26 (20.2)22 (14.4)4 (1.4)6 (2.3) *Streptococcus mitis*2 (1.6)7 (4.6)---- *Streptococcus salivarius*2 (1.6)2 (1.3)---- *Streptococcus sanguinis*4 (3.1)2 (1.3)---- *Streptococcus viridans* group3 (2.3)7 (4.6)----Gram-positive anaerobes7 (5.4)6 (3.9)3 (1.1)7 (2.7) *Clostridium perfringens*4 (3.1)2 (1.3)----Gram-negative aerobes4 (3.1)5 (3.3)5 (1.8)2 (0.8)Monomicrobial baseline infection105 (81.4)131 (85.6)250 (90.3)231 (89.2)Polymicrobial baseline infection24 (18.6)22 (14.4)27 (9.7)28 (10.8)*IDU* injection drug user, *MITT* microbiological intent-to-treat, *MRSA* methicillin-resistant *S. aureus*, *MSSA* methicillin-susceptible *S. aureus*, *non-IDU* non-injection drug user^a^Percentage is calculated with total number of *S. aureus* in each group as the denominator

Efficacy {#Sec11}
--------

Early clinical response rates in the ITT population at the 48- to 72-h visits were similar in IDUs treated with tedizolid \[82.5% (151/183)\] or linezolid \[79.6% (164/206); Fig. [1](#Fig1){ref-type="fig"}\]. For IDUs, the treatment difference between tedizolid and linezolid was 2.9% (95% CI − 4.9, 10.7). Similarly, for non-IDUs, early clinical response was comparable between tedizolid-treated patients \[81.3% (391/481)\] and linezolid-treated patients \[79.3% (367/463)\] (Fig. [1](#Fig1){ref-type="fig"}). Early response rates did not differ between IDUs and non-IDUs (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Early clinical response at the 48- to 72-h visits by injection drug use in the intent-to-treat population. Early clinical response was defined as ≥ 20% reduction in lesion size. Early clinical response rates for the tedizolid and linezolid treatment groups were similar in IDUs and non-IDUs. *IDUs* injection drug users, *non-IDUs* non-injection drug users

In the ITT population, the rates of clinical success based on investigator assessment of clinical response at the PTE visit were similar between IDUs and non-IDUs treated with tedizolid \[83.1% (152/183) and 88.1% (424/481), respectively\] or linezolid \[84.0% (173/206) and 88.1% (408/463), respectively\] (Fig. [2](#Fig2){ref-type="fig"}a). The treatment difference between tedizolid and linezolid was − 0.9% (95% CI − 8.3, 6.5) for IDUs. Clinical success rates in the CE-PTE population were also comparable between IDUs treated with tedizolid and linezolid (Fig. [2](#Fig2){ref-type="fig"}b), with a treatment difference of − 1.0% (95% CI − 6.8, 4.2) in IDUs. Similar clinical success rates were observed for IDUs and non-IDUs at the PTE visit in both the ITT (83.1--88.1%) and the CE-PTE (93.4--96.1%) populations (Fig. [2](#Fig2){ref-type="fig"}a, b).Fig. 2Clinical success rates at the PTE by injection drug use in the **a** ITT population and the **b** CE-PTE population. No differences in clinical response rates at the PTE were observed between tedizolid and linezolid treatment or between IDUs and non-IDUs in the ITT or CE-PTE population. *CE* clinically evaluable, *IDUs* injection drug users, *ITT* intent-to-treat, *non-IDUs* non-injection drug users, *PTE* post-therapy evaluation

Rates of favorable microbiological response per baseline pathogen at the EOT visit for the MITT and ME-EOT populations are presented in Table [3](#Tab3){ref-type="table"}. Rates were generally similar between both treatment groups in IDUs and non-IDUs from the MITT and ME-EOT populations at EOT (Fig. [3](#Fig3){ref-type="fig"}a, b). Microbiological response to *S. anginosus* was lower for tedizolid than for linezolid in IDUs from the MITT population at EOT. However, at the PTE visit, high response rates were observed with both treatments in IDUs and non-IDUs (\> 80% positive response in the MITT population and \> 90% positive response in the ME-PTE population) (Fig. [3](#Fig3){ref-type="fig"}c, d).Table 3Rates of favorable microbiological response per baseline pathogen at EOT visitFavorable response, *n*/*N* (%)MITT populationME-EOT populationIDUNon-IDUIDUNon-IDUTedizolidLinezolidTedizolidLinezolidTedizolidLinezolidTedizolidLinezolidGram-positive aerobes129/151 (85.4)145/170 (85.3)301/332 (90.7)276/301 (91.7)116/121 (95.9)136/142 (95.8)270/282 (95.7)245/246 (99.6) *Staphylococcus aureus*92/100 (92.0)105/120 (87.5)237/261 (90.8)226/246 (91.9)83/87 (95.4)97/100 (97.0)215/224 (96.0)200/201 (99.5)  MRSA35/41 (85.4)38/47 (80.9)96/111 (86.5)96/110 (87.3)33/36 (91.7)34/36 (94.4)90/96 (93.8)86/87 (98.9)  MSSA57/59 (96.6)67/73 (91.8)141/150 (94.0)129/135 (95.6)50/51 (98.0)63/64 (98.4)125/128 (97.7)113/113 (100.0) *Streptococcus pyogenes*--1/1 (100.0)38/39 (97.4)19/20 (95.0)--1/1 (100.0)32/32 (100.0)18/18 (100.0) *Streptococcus anginosus* group18/26 (69.2)20/22 (90.9)4/4 (100.0)5/6 (83.3)16/17 (94.1)20/21 (95.2)3/3 (100.0)3/3 (100.0) *Streptococcus mitis*2/2 (100.0)6/7 (85.7)----2/2 (100.0)5/5 (100.0)---- *Streptococcus salivarius*1/2 (50.0)2/2 (100.0)----1/1 (100.0)2/2 (100.0)---- *Streptococcus sanguinis*2/4 (50.0)0/2 (0.0)------------ *Streptococcus viridans* group2/3 (66.7)3/8 (37.5)----2/2 (100.0)3/5 (60.0)----Gram-positive anaerobes7/8 (87.5)4/7 (57.1)4/4 (100.0)8/9 (88.9)5/5 (100.0)4/6 (66.7)3/3 (100.0)5/5 (100.0) *Clostridium perfringens*4/4 (100.0)1/2 (50.0)----4/4 (100.0)1/1 (100.0)----Gram-negative aerobes4/6 (66.7)5/6 (83.3)3/8 (37.5)2/2 (100.0)4/4 (100.0)5/5 (100.0)2/4 (50.0)1/1 (100.0)*EOT* end of treatment, *IDU* injection drug user, *MITT* microbiological intent-to-treat, *ME* microbiologically evaluable, *MRSA* methicillin-resistant *S. aureus*, *MSSA* methicillin-susceptible *S. aureus*, *non-IDU* non-injection drug user Fig. 3Favorable microbiological response by injection drug use. **a** EOT evaluation for the MITT population. **b** EOT evaluation for the ME-EOT population. **c** PTE for the MITT population. **d** PTE evaluation for the ME-PTE population. No difference in favorable microbiological response was observed between tedizolid and linezolid treatment in IDUs and non-IDUs in these populations. *EOT* end-of-therapy, *IDUs* injection drug users, *ME* microbiologically evaluable, *MITT* microbiological intent-to-treat, *non-IDUs* non-injection drug users, *PTE* post-therapy evaluation

Safety {#Sec12}
------

The incidence of treatment-emergent adverse events (TEAEs) was slightly elevated in IDUs compared with non-IDUs. TEAEs occurred in 46.2% (84/182) of tedizolid patients and 47.8% (97/203) of linezolid patients who used injection drugs; in non-IDUs, 41.5% (199/480) of tedizolid patients and 41.2% (189/459) of linezolid patients reported experiencing any TEAE (Table [4](#Tab4){ref-type="table"}). TEAEs under the grouping "infections and infestations" were more common among IDUs than non-IDUs, particularly new, secondary abscess or cellulitis. In the tedizolid group, 8.2% (15/182) of IDUs and 4.2% (20/480) of non-IDUs experienced secondary abscess; 4.4% (8/182) and 1.9% (9/480), respectively, had secondary cellulitis. Results were similar in the linezolid group: 6.9% (14/203) and 2.6% (12/459) of IDUs and non-IDUs, respectively, had secondary abscess and 3.4% (7/203) and 1.5% (7/459), respectively, had secondary cellulitis.Table 4Summary of adverse events by injection drug use (safety population)Adverse event, *n* (%)IDU (*N* = 385)Non-IDU (*N* = 939)Tedizolid (*n* = 182)Linezolid (*n* = 203)Tedizolid (*n* = 480)Linezolid (*n* = 459)All AEs86 (47.3)97 (47.8)203 (42.3)191 (41.6)Any TEAE84 (46.2)97 (47.8)199 (41.5)189 (41.2)Drug-related TEAE50 (27.5)68 (33.5)98 (20.4)117 (25.5)Moderate/severe TEAE28 (15.4)42 (20.7)60 (12.5)51 (11.1)Serious TEAE5 (2.7)4 (2.0)7 (1.5)9 (2.0)Drug-related serious TEAE0 (0.0)1 (0.5)0 (0.0)1 (0.2)TEAE leading to discontinuation2 (1.1)3 (1.5)1 (0.2)3 (0.7)TEAE leading to death1 (0.5)0 (0.0)1 (0.2)1 (0.2)TEAE (≥ 2% in frequency) Abscess15 (8.2)14 (6.9)20 (4.2)12 (2.6) Cellulitis8 (4.4)7 (3.4)9 (1.9)7 (1.5) Diarrhoea9 (4.9)12 (5.9)17 (3.5)23 (5.0) Dizziness5 (2.7)4 (2.0)7 (1.5)10 (2.2) Fatigue0 (0.0)2 (1.0)9 (1.9)10 (2.2) Headache6 (3.3)10 (4.9)35 (7.3)29 (6.3) Nausea17 (9.3)33 (16.3)37 (7.7)48 (10.5) Pruritus1 (0.5)5 (2.5)2 (0.4)4 (0.9) Vomiting11 (6.0)13 (6.4)8 (1.7)24 (5.2) Wound infection5 (2.7)2 (1.0)1 (0.2)0 (0.0)Patients reporting an AE were counted only once*AE* adverse event, *IDU* injection drug user, *non-IDU* non-injection drug user, *TEAE* treatment-emergent adverse event

Among the most frequently reported TEAEs (≥ 2%), gastrointestinal (GI) disorders (including nausea, vomiting, and diarrhea) were most common and were higher in the linezolid arm in both IDUs and non-IDUs. GI TEAEs in IDUs were reported in 20.3% (37/182) of the tedizolid group compared with 25.1% (51/203) of the linezolid group, which was slightly higher than rates reported in non-IDUs \[tedizolid, 14.4% (69/480); linezolid, 22.0% (101/459)\]. Three deaths occurred during the study; one of those who died was a patient actively using injection drugs. This patient developed septic shock with multiorgan failure and died 46 days after receiving the final dose of tedizolid. All deaths were considered unrelated to the study drug \[[@CR19]\].

Discussion {#Sec13}
==========

ABSSSI is a leading reason that IDUs seek medical treatment \[[@CR2], [@CR4]\]. Treatment of this patient group frequently rests with emergency physicians as many IDUs utilize emergency departments as their primary source of medical care \[[@CR2], [@CR4]\]. Effective antibacterial treatment relies heavily on the appropriateness of initial therapy and first-line treatment in the emergency department is critical to ensuring successful outcomes in this patient population.

In this post hoc subgroup analysis from two phase 3 clinical trials of tedizolid, IDUs overall had fewer traditional systemic signs and symptoms of infection (fever, abnormal white blood cell counts, SIRS, and immature neutrophils) than non-IDUs. However, lymphadenopathy, hepatitis C, poor living conditions, and past ABSSSI lesions were more prevalent in IDUs, consistent with reported conditions known to be common in this population \[[@CR7], [@CR13], [@CR23], [@CR24]\]. The higher incidence of secondary skin infections and hepatitis C is unsurprising given that IDUs repeatedly inject into various anatomic sites which all have the potential for infection.

The distribution of ABSSSI types differed between IDUs and non-IDUs. As would be expected from repeated injections, more than half of IDUs had wound infections, whereas non-IDUs predominantly had cellulitis/erysipelas, similar to what was observed in the overall ITT population \[[@CR19]\]. It is possible that some infections in IDUs classified as cellulitis/erysipelas or abscess were related to an injection site and might therefore be considered wound infections or vice versa.

The majority of ABSSSI in both IDUs and non-IDUs were due to *S. aureus*. However, infections in IDUs were associated with a more diverse range of bacterial species not typically causative of ABSSSI, specifically those of the oral flora. These species increase the risk for infection from oral streptococcal and Gram-positive anaerobic species \[[@CR6], [@CR7]\]. The findings from this study are consistent with previous reports that found *S. aureus* to be the predominant causative pathogen in ABSSSI with oral pathogens constituting higher proportions among IDUs \[[@CR4], [@CR10]\].

Despite differences in baseline patient and clinical characteristics, treatment outcomes in both IDUs and non-IDUs were comparable with tedizolid and linezolid at both the early evaluation and the PTE. Early clinical response approximated 80% for IDUs and non-IDUs in both treatment arms. This rate was similar to that observed in the overall, pooled ITT population, as reported \[[@CR19]\]. Investigator-assessed clinical response at PTE was also comparable between treatment arms and IDU/non-IDU patient populations. Similarities in clinical outcomes suggest that complicating factors associated with injection drug use did not greatly impact the efficacy profile of tedizolid or linezolid in treating ABSSSI. The microbiological response of IDUs was also generally similar to that of non-IDUs in the MITT and ME populations, despite the greater diversity of pathogens in the IDU group and regardless of treatment arm. At EOT and PTE, high response rates were observed for both treatments in IDUs, and \> 90% of pathogens were eradicated or presumed eradicated with either treatment in both IDUs and non-IDUs in the ME population.

Overall, tedizolid and linezolid were well tolerated in IDUs, although the rate of TEAEs was slightly higher in IDUs than in non-IDUs. In both treatment groups, IDUs experienced secondary abscesses and secondary cellulitis more often than non-IDUs, although this could be associated with new infections caused by repeated needle use in other locations. GI disorders also occurred at a higher frequency in IDUs, with a numerically greater incidence in the linezolid group than in the tedizolid group, consistent with safety results observed in the overall ITT population \[[@CR19]\]. These GI TEAEs generally occurred within the first 6 days of treatment. As such, they were likely the result of pharmacologic differences between linezolid and tedizolid and not a result of the shorter course of therapy with tedizolid phosphate \[[@CR19]\].

The high-risk lifestyle of IDUs, often coupled with increased rates of reinfection and concomitant mental health issues, makes compliance a major concern in this treatment population \[[@CR2], [@CR11], [@CR13], [@CR25]\]. In a systematic review of patient adherence to oral antibacterials, medical compliance was higher in patients prescribed once-daily, short-course oral therapy than in patients prescribed longer and more frequent regimens \[[@CR26]\]. The convenience and effectiveness of a once-daily, short-course oral treatment such as tedizolid phosphate may be particularly beneficial in this population. Reducing pill burden has the potential to increase treatment compliance and optimize outcomes in a real-world setting. IDUs may also be at risk for serotonin syndrome, a potentially life-threatening reaction caused by overactivation of the serotonergic system \[[@CR27]\]. Many cases of serotonin syndrome are caused by unintended drug--drug interactions, and it is known that some drugs of abuse can lead to serotonin toxicity \[[@CR27]\]. Tedizolid may be less likely to cause serotonin syndrome than linezolid, though further research is required to support this hypothesis \[[@CR28], [@CR29]\].

Several limitations should be considered when evaluating the results of this study. This was a post hoc subgroup analysis of a patient subpopulation and might have lacked sufficient power to detect differences between IDUs and non-IDUs. The study relied on self-reporting of injection drug use, which might have been subject to underreporting. In addition, the two treatment groups within the IDU and non-IDU subgroups might not have been balanced with respect to all prognostic factors.

Conclusion {#Sec14}
==========

In summary, although IDUs present with treatment challenges not typically seen in non-IDUs, clinical outcomes were similar for both patient populations. Both tedizolid and linezolid were well tolerated; however, fewer GI AEs were associated with tedizolid treatment. This study showed that short-course, 6-day treatment with tedizolid was as effective as 10 days of linezolid in treating ABSSSI in IDUs, which suggests that tedizolid (including exclusively oral treatment) is a suitable treatment option in this complex patient population.
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